Filtered By:
Source: Current Pharmaceutical Design

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 176 results found since Jan 2013.

Long Noncoding RNAs as Diagnostic and Therapeutic Targets for Ischemic Stroke.
Abstract LncRNAs (long non-coding RNAs) are endogenous molecules lacking protein-encoding capacity, which have been identified as key regulators of ischemic stroke. Increasing evidence suggests that lncRNAs play critical roles in several aspects of ischemic stroke, including atherosclerosis, dyslipidemia, hypertension, and diabetes mellitus. Hence, lncRNAs may further broaden our understanding of stroke pathogenesis. Altered lncRNA expression has been found in rodent focal cerebral ischemia models and oxygen-glucose deprived mouse brain microvascular endothelial cells as well as stroke patients. LncRNAs are consid...
Source: Current Pharmaceutical Design - March 26, 2019 Category: Drugs & Pharmacology Authors: Wang Q, Liu X, Zhu R Tags: Curr Pharm Des Source Type: research

Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future.
CONCLUSION: Thrombolytic therapy is sometimes accompanied by harmful hemorrhagic insults; accordingly, a window of time wherein therapy can safely be performed has been established for this approach. Several basic and clinical studies are ongoing to develop next-generation thrombolytic drugs to expand the time window. PMID: 30892155 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - March 17, 2019 Category: Drugs & Pharmacology Authors: Shibata K, Hashimoto T, Miyazaki T, Miyazaki A, Nobe K Tags: Curr Pharm Des Source Type: research

An update on the association of protein kinases with cardiovascular diseases.
CONCLUSION: ROCK inhibitors, fasudil and Y27632, have been reported for significant efficiency in dropping vascular smooth muscle cell hyper-contraction, vascular inflammatory cell recruitment, cardiac remodelling and endothelial dysfunction which highlight their role in cardiovascular diseases. PMID: 30864507 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - March 10, 2019 Category: Drugs & Pharmacology Authors: Amin F, Ahmad A, Feroz A, Khaqi SS, Khan MS, Tabrez S, Zaidi SK, Abulaal WH, Shamsi A, Khan W, Bano B Tags: Curr Pharm Des Source Type: research

Predictive Value of Methods Measuring Platelet Activation for Ischemic Events in Patients Receiving Clopidogrel: A Meta-analysis.
This study investigates the efficiency and predictive value of light-transmission aggregometry (LTA), vasodilator-stimulated phosphoprotein (VASP) and VerifyNow for ischemia in patients undergoing percutaneous coronary intervention (PCI). Studies that used LTA, VASP or VerifyNow to predict ischemia were included, and their quality and efficiency were analyzed using Review Manager 5.3. The sensitivity and specificity of subgroup studies based on the outcome, cut-off value, and follow-up days were calculated and the summary ROC (sROC) curves were compared after having been fitted. Thirty-one studies including a total of 17,3...
Source: Current Pharmaceutical Design - February 5, 2019 Category: Drugs & Pharmacology Authors: Wang Z, Xie Q, Xiang Q, Gong Y, Jiang J, Cui Y Tags: Curr Pharm Des Source Type: research

Monocyte as an Emerging Tool for Targeted Drug Delivery: A Review.
Abstract Monocytes are leading component of the mononuclear phagocytic system that play a key role in phagocytosis and removal of several kinds of microbes from the body. Monocytes are bone marrow precursor cells, stay in the blood for few days and migrate towards tissues where they differentiate into macrophages. Monocytes can be used as a carrier for delivery of active agents into tissues, where other carriers have no significant access. Targeting monocytes is possible both through passive and active targeting, the former one is simply achieved by enhanced permeation and retention effect while the later one by a...
Source: Current Pharmaceutical Design - January 1, 2019 Category: Drugs & Pharmacology Authors: Sabir F, Farooq RK, Asim Ur Rehman, Ahmed N Tags: Curr Pharm Des Source Type: research

Novel Oral Anticoagulants in Peripheral Artery Disease. Current Evidence.
CONCLUSION: For the time being, novel oral anticoagulants in combination with aspirin may provide an alternative treatment in PAD, however, it is deemed necessary to identify patient subgroups who will benefit the most. PMID: 30585539 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - December 26, 2018 Category: Drugs & Pharmacology Authors: Koutsoumpelis A, Argyriou C, Tasopoulou KM, Georgakarakos EI, Georgiadis GS Tags: Curr Pharm Des Source Type: research

The role of calcium handling mechanisms in reperfusion injury.
Abstract Cardiovascular diseases, such as stroke and myocardial infarction (MI) remain the major cause of death and disability worldwide. However, the mortality of MI has declined dramatically over the past several decades because of advances in medicines (thrombolytic agents, antiplatelet drugs, beta blockers, and angiotensin converting enzyme inhibitors) and approaches to restore tissue perfusion(percutaneous coronary intervention and cardiopulmonary bypass). Animals studies have been shown that these treatments have been effective in reducing acute myocardial ischemic injury and limiting MI size. The paradox is...
Source: Current Pharmaceutical Design - November 20, 2018 Category: Drugs & Pharmacology Authors: Pittas K, Vrachatis DA, Angelidis C, Tsoucala S, Giannopoulos G, Defteros S Tags: Curr Pharm Des Source Type: research

Brain Peptides for the Treatment of Neuropsychiatric Disorders.
Abstract The realization of the importance of growth factors in adult CNS led to several studies investigating their roles in neuropsychiatric disorders. Based on the observations that chronic stress decreases brain-derived neurotrophic factor (BDNF) and antidepressant treatments reverse BDNF to normal levels, "neurotrophic hypothesis of depression" was proposed. Subsequent studies found that several other growth factors, including fibroblast growth factor (FGF), vascular endothelial growth factor, nerve growth factor were also decreased by chronic stress. Growth factors promote stem cell survival, angiogenesis an...
Source: Current Pharmaceutical Design - November 11, 2018 Category: Drugs & Pharmacology Authors: Karatas H, Yemisci M, Eren-Kocak E, Dalkara T Tags: Curr Pharm Des Source Type: research

Effects of ABCB1 genotypes on the pharmacokinetics and clinical outcomes of new oral anticoagulants: A systematic review and meta-analysis.
Conclusions Cmax was lower in carriers of ABCB1 rs1045642 CC than in those of TT and in carriers of rs2032582 GG than in those of the A/T allele, and AUC0-∞ was lower in carriers of rs1045642 CC than in those of TT. Conversely, ABCB1 rs4148738 genotypes did not affect primary clinical endpoints in dabigatran-administered patients. Future studies should analyze the relationships of ABCB1 genotypes with the pharmacokinetics and clinical outcomes of specific NOACs. PMID: 30338730 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - October 18, 2018 Category: Drugs & Pharmacology Authors: Xie Q, Xiang Q, Mu G, Ma L, Chen S, Zhou S, Hu K, Zhang Z, Cui Y, Jian J Tags: Curr Pharm Des Source Type: research

Is very low LDL-C harmful?
CONCLUSION: Achieving an LDL-C of 40-50 mg/dl seems to be safe, and importantly might offer CV beneficial effects. Data for attaining levels below 25 mg/dl is limited, however in favor of such reductions. PMID: 30295187 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - October 8, 2018 Category: Drugs & Pharmacology Authors: Faselis C, Imprialos K, Grassos H, Pittaras A, Kallistratos M, Manolis A Tags: Curr Pharm Des Source Type: research

Does HbA1cc Play a Role in the Development of Cardiovascular Diseases?
In conclusion, HbA1c serves as a useful marker for diagnosis and management of diabetes. AGE cannot replace HbA1c in the diagnosis and management of diabetes. There is an association of HbA1c with CVD which be mediated through modulation of CVD risk factors. PMID: 30179123 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - September 3, 2018 Category: Drugs & Pharmacology Authors: Prasad K Tags: Curr Pharm Des Source Type: research

The Mechanism of Exosomes Function in Neurological Diseases: a progressive review.
Abstract Exosomes are extracellular microparticles (≈30-100 nm in diameter) secreted from nearly all types of cells, containing a whole set of biological information including proteins, ribonucleic acid (RNA) and lipids. Latest studies show that exosomes contribute to cell-cell communication and are considered closely related with the modulation of angiogenesis and neurogenesis in many neurological diseases. In past decade, numerous researchers were devoted to exosomes study, but the mechanism of exosomes function and delivery is uncertain. In this review, we summarized several potential mechanisms of exosomes f...
Source: Current Pharmaceutical Design - September 2, 2018 Category: Drugs & Pharmacology Authors: Yuan M, Liu N, Wang X, Tian C, Ren X, Zhang H, Li X, Zhu H, Zhu L, Shang H, Xing Y, Gao Y Tags: Curr Pharm Des Source Type: research

Thioredoxin as a therapeutic target in cerebral ischemia.
CONCLUSION: In conclusion, Trx has a potential neuroprotection in cerebral ischemia and may be very promising for clinical therapy of ischemic stroke in the future. PMID: 30124144 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 20, 2018 Category: Drugs & Pharmacology Authors: Zeng XS, Geng WS, Chen L, Jia JJ Tags: Curr Pharm Des Source Type: research

Role of heme oxygenases in cardiovascular syndromes and co-morbidities.
CONCLUSIONS: Each of the six major categories of CVD exhibit features of pathogenesis that hold potential as future therapeutic targets, for modulated heme oxygenase activity. PMID: 30051777 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - July 26, 2018 Category: Drugs & Pharmacology Authors: Haines DD, Tosaki A Tags: Curr Pharm Des Source Type: research

Heme oxygenase-1: clinical relevance in ischemic stroke.
Abstract Stroke is the second-leading cause of death and a leading cause of serious long-term disability worldwide, with an icreasing global burden due to the growing and aging population. However, strict eligibility criteria for current treatment opportunities make novel therapeutic apporaches desirable. Oxidative stress plays a pivotal role during cerebral ischemia, eventually leading to neuronal injury and cell death. The significant correlation between redox imbalance and ischemic stroke has led to various treatment strategies targeting the endogenous antioxidant system in order to ameliorate the adverse progn...
Source: Current Pharmaceutical Design - July 16, 2018 Category: Drugs & Pharmacology Authors: Bereczki D, Balla J, Bereczki D Tags: Curr Pharm Des Source Type: research